1. Medtech Insight
  2. >>Policy & Regulation

FDA Approves Abbott Xience DES For Short Dual-Antiplatelet Course

 
• By Reed Miller

The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.

Abbott's Xience Skypoint Everolimus-Eluting Stent
Abbott's Xience Skypoint Everolimus-Eluting Stent • Source: Abbott

Abbott’s Xience everolimus-eluting stent has joined the group of drug-eluting coronary stents approved by the US Food and Drug Administration for patients at high risk of bleeding.

On 30 June, the company announced the FDA approval for an expanded indication for the Xience line of stents that includes patients at high risk of bleeding, including those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.